Median progression-free survival was 11.0 months and median overall survival was 21.6 months for these crossover patients, Dr. Molina and co-investigators reported.
No patients in the study had a complete response, while 29 (18%) had a partial response and 83 (52%) had stable disease.
“These data compare favorably with other second-line therapies for RCC,” Dr. Molina and co-authors said.
Grade 3 or greater adverse events occurred in 48% of patients, including 24% that were treatment related. The most common grade 3 treatment-related adverse event was hypertension in 11%.